DOCSLIB.ORG

The La Tarde Dine Hii Na Kuwa Na Matatu

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The La Tarde Dine Hii Na Kuwa Na Matatu THELA TARDE DINEUS 20180085423A1 HII NAKUWA NA MATATU ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2018 / 0085423 A1 ZELTSER et al. (43 ) Pub . Date : Mar . 29 , 2018 ( 54 ) METHODS FOR TREATING AND ( 60 ) Provisional application No . 62 / 148, 698 , filed on Apr . DIAGNOSING EATING DISORDERS 16 , 2015 . ( 71 ) Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF Publication Classification NEW YORK , New York , NY (US ) (51 ) Int. Cl. A61K 38 / 08 ( 2006 .01 ) ( 72 ) Inventors : Lori Michelle ZELTSER , New York , A61K 9 / 00 (2006 . 01) NY (US ) ; Rim HASSOUNA , New (52 ) U . S . CI. York , NY (US ) ; Moneek MADRA , CPC . .. .. A61K 38 /08 (2013 .01 ) ; A61K 9 /0019 New York , NY (US ) ( 2013 .01 ) (73 ) Assignee : THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF ( 57 ) ABSTRACT NEW YORK , New York , NY ( US) The present invention provides methods of treating or pre venting an eating disorder , including anorexia nervosa, by ( 21 ) Appl. No. : 15 / 784, 927 administering a vasopressin Vla receptor (AVPR1A ) antago (22 ) Filed : Oct. 16 , 2017 nist. The present invention also provides methods of diag nosing the presence of or predisposition to an eating disor Related U . S . Application Data der, including anorexia nervosa, in a subject , comprising (63 ) Continuation - in -part of application No . PCT /US16 / detecting the presence and / or level of arginine vasopressin 25209, filed on Mar . 31, 2016 . ( AVP ) or AVPR1A in a the subject. Patent Application Publication Mar .29 , 2018 Sheet l of 15 US 2018 / 0085423 A1 FIGERES LA . C ? , ? . inBeiMiki ?????: ?????????????????????????? … … … * * * * * * * * *. *. A. A4. A. 4. A. 4. A . is: www … … … . ? , ? ? : : : : : * … . * adidas …. … * .… 32? Patent Application Publication Mar . 29 , 2018 Sheet 2 of 15 US 2018 / 0085423 A1 FIGURES 2A - E * .. * volano33120)( Aclaruma * Against * & renk GES e cop Genadype Vai Very VaVa fer ? Valla Vet ? Ket ? Me ? Socialisolation Swks Swks 52V4S SES Swks Swks Caloxio restrictions : ?Wawks 9002 7wks we erale siis 60 Vaivat, isolated CR 660 Meti ? , solated , CR * 8 * . RUGOMBEIGUOA( VORM wwwwwwwww Time ( days) Gengiyon Vaiwa Beyin Socialisation ms Ssuks . Caloric restriction 70ks !uks Patent Application Publication Mar . 29 , 2018 Sheet 3 of 15 US 2018 / 0085423 A1 FIGURES 3A - D FIGURE 3A FIGURE 3B GE : Marcolets QED : Met ? Soate . CR . ' BELRIES Animal -. * 0 @ Gento . Ma Me Wet ' ? We Sock soku wkS is ots Swis Czerc tastietoa 7KS KS Age of addiya : 7 . 9 XKS 9 Suks 7 . 9 .5wks vs FIGURE 3C Aegningai ?????????? GE GED GER GEDI Genovo M Mer Mers Focal 5W * S XS SWS Cok * * 9Sokie stort . - W WYS Zwks Caic restriction levels FIGURE 3D everything Pu ;???????????.????????????????????????????????????????????????????????? www GEO GEO GERD EO seg Caloge . Motor ? VoW VO VW Soosao Swisks SWS SKS AWS CHem WSW wts was awks Basi - Patent Application Publication Mar . 29 , 2018 Sheet 4 of 15 US 2018 / 0085423 A1 FIGURES 4A - C FIGURE 4A Es coin DocemucoucoWines Ouru) wwwwwwwwwwwwwwwww GED-6 CEDAE GEDH FIGURE 4B x in RelativeRIAvoriaugge-uossadxo dewiii GEDOGEDAE GEDH FIGURE 4C o ? ina RelativePTAvonta Expression(B-scani ? o ? GEDGED -AE CED Patent Application Publication Mar . 29 , 2018 Sheet 5 of 15 US 2018 / 0085423 A1 FIGURES 5A - C FIGURE 5A ??.???????????????????????????????????? vogelduOUOOWNBS (wow! 0 G GE FIGURE 5B (unde-il)voiss?loxe LOAFUdang 1 C . GE GE FIGURE 5C expression(ft-actin . FelativePITaprId nes. C G EGE Patent Application Publication Mar . 29 , 2018 Sheet 6 of 15 US 2018 / 0085423 A1 FIGURES 6A - E FIGURE 6A FIGURE 6B * ANG : AVO AMG : Avoria B . Relativeexpression f-actin torstadoSAMO (B-actio) C G D GE G dengan GE FIGURE 6C FIGURE 6D . PFO : Avoria AC: Avoria 2-22222222 BAJOdx9voissa. (une-) 04. Relativeexpression 6-act © GECE FIGURE 6E 0dH qurday MOSSJoxeonneay (-actin) 2 C G GE Patent Application Publication Mar . 29 , 2018 Sheet 7 of 15 US 2018 / 0085423 A1 FIGURES 7A - G FIGURE A FIGURE 7B 200 .000 190. 000 T L counts) * Totalactivity(counts) KISWA MILARDEPORNO 99 .000 Genotype Verval meu ? Vama Ves ? Valva Very Vama Seu ? Skaistian - WS - 1 SWS SWS Movel environmentEuli: 6 - 765 6 -7XS 6 - wks 6 -7wks lili FIGURE 7C FIGURE 7D FIGURE 7E R HYP -Ohr R HYP : 0 to RHYO :Crir > * > e *. (P-actist) (B-actin) iet m (6-sotin Relativeexpression toissaldosajejo Relativeexpression .* N wwwwwwwwwwwwww o C G G C 6 GE FIGURE 7F FIGURE 7G Saseline 0 Absolute dhcrease mare wwwww (ng/dL)file (ng/dL) celemai QuojasOODOO B 4444444 Corticosterone @ GED - 0 GED -AS GED . GED -AE Patent Application Publication Mar . 29 , 2018 Sheet 8 of 15 US 2018 / 0085423 A1 FIGURES 8A - F FIGURE 8A FIGURE SB . o WdAH ild Owuod *ngingin Relativeexpression (B-acun topo Relativeexpression(unge-91) seminarioesconditioniniocom* C G GE CGGE FIGURE THI8C FIGURE 8D Adrenalweight baseline restraint * UQSisomopów)( (bbw)14610M 890 * jeuaipeajela WWWWWWWWWW ? 88 * GGE. C. G GE Patent Application Publication Mar . 29 , 2018 Sheet 9 of 15 US 2018 / 0085423 A1 FIGURE SE (counts) Centraltotalactivity ???????.??????????????????????????????????? C GEGE Genotype : Valdal Met ? Val/ Val Met ? Social isolation : 5 -6wks 5 -6wks Novel environment: 6 -7wks 6 - 7wks 6 - 7wks 6 - 7wks FIGURE 8F 200000. - Totalactivity(counts) 50000 C G E GE Patent Application Publication Mar . 29 , 2018 Sheet 10 of 15 US 2018 /0085423 A1 FIGURES 9A - B FIGURE 9A AE/animal W wwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwww ww GE GEDH Genotype Met ? Met ? Social isolation : 5wks 5wks Caloric restriction : 7wks 7wks Handling 2 6wks FIGURE 9B R88 WLLLL LLLLLLLLLL Corticosterone(ug/dL) * * * www.qwqwyu? * 89 ??????????????????????????? * ??? GEDH baseline O restraint Patent Application Publication Mar . 29 , 2018 Sheet 11 of 15 US 2018 /0085423 A1 FIGURES 10A - D FIGURE 10A FIGURE 10B FIGURE 10C FIGURE 10D * * .. * X * BOX * ,.4 X*XXKM W ,. , , * * mmmmmmm 6 : * Serum AVP AMYG"! :Avprla "! "! AMYG :Avp AMYG: Ngfr Patent Application Publicati0ll Mar . 29 , 2018 Sheet 12 0f15 US 2018/ 0085423 Al FIGURE11 Saline GED - AE Corripound 1 ug/ kg GED - AE A Saline WT- Fasted ? f Commpound 1 ug / kg NT -Fasted 1? CurmulativefoodIntake(g) ? ? ?3 G84 ?-1. | _.i• 1:4 ? ? ?? ? ? His ? 2h Time after injection Patent Application Publication Mar . 29 , 2018 Sheet 13 of 15 US 2018 /0085423 A1 FIGURES 12A - I 0062656 :40 12: 45 065 : 8 ) VAGINAS GENERIC MOMENTAS YEAR 30 MM S . ad rem o con GSA3254 wie ( 66 .6802 uselesa: 0004 o 12 mescissis 6 628105 We 8x8 Axence . Sms Sport kuoad Mediat Sook c xana Avota Aloto highesiaktive i 2000 . : . 2403Skogi?i Quoo 1. las Rediveakiyesion tn:act PEG LOIESAISXSStuckyCongo XXIKVRUSAK os 20003 - C AME s90 CEDO GEDAAN ROM root BONE Vacant Our valle 60X100 Sot RÓKI Socis solajor Sms Sc404 S04 13 . 8 .. BIORESO Cabric tesko * . Cantoresco algoYesuais wska Dvorts Airo M ees voor 1000043 Backin) (092-300 acra asoch8/10800 NOSRXONAawe enon plavespesso Piana4veroom on goa * G SE 96 *!W SON 768xe ! . CONV:58 0.4 DONE sfonat o rer : * LLLSocial Scinoo . * Soch saken soosis : 0 j Socet Isocom : Patent Application Publication Mar . 29 , 2018 Sheet 14 of 15 US 2018 /0085423 A1 FIGURES 13A - C . :'d D Saline Wild type AVP 0. 03ng 16 per group Cumulativefoodintake(9) 30 min 1 2h 4h Tints after injection 0 Saline AVP 0 .0300 AVPR1A KO n - 4 per zroup cumulaivefoodintake(0) 30 mini 11 21 h ?????? {{ ?? ? Patent Application Publication Mar . 29 , 2018 Sheet 15 of 15 US 2018 /0085423 A1 FIGURES 14A - B B 63line 103. Saline 1. .. AVPCV Saline ja m AvoicV Manning Compounds. * AVPLOV * R49050 1. D . Ourrulauvafoodintake(9) . ac bo W Time after injection O Salne CED - AE m Manning Compound GEO -AE W SR49059 GEO -AE g Sahne W - Fastad . Curnulativefoodintake( . 24 Time after injection (saline , avp + saline , avp +manning , avp + SR49059 ;75 , 4 , 5 , 4 ) (GED -AE saline , Manning , SR49059 ; n = 4 , 4 , 3 ) (WT saline, Manning SR49059 , n = 10 . 5 , 5 ) US 2018 /0085423 A1 Mar . 29 , 2018 METHODS FOR TREATING AND receptor antagonist to the subject, to thereby modulate DIAGNOSING EATING DISORDERS eating behavior in the subject . [0007 ] In one embodiment of the foregoing aspects, the RELATED APPLICATIONS vasopressin V , receptor antagonist can be , for example , a small molecule antagonist, such as, but not limited to , [0001 ] This application is a continuation -in -part of Inter 1 - (beta -mercapto -beta beta - cyclopentamethylenepropionic national Application No. PCT/ US2016 /025209 , filed Mar. acid ) - 2 - ( 0 -methyl - Tyr ) -argipressin , SR49049 (Relcovap 31 , 2016 , which claims the benefit of priority to U . S . tan ) , atosiban ( Tractocile® ) , conivaptan ( YM - 087 ) , VPA Provisional Patent Application No. 62 / 148 ,698 , filed Apr. 985 (Lixivaptan ), CL - 385004 , Vasotocin , SRX251 and 16 , 2015 . The contents of these applications are incorporated SRX246 ( Azevan ) , YM - 218 (Astellas ), OPC -2158 ( Otsuka ), herein by reference in their entirety . and OPC21268 , or a pharmaceutically acceptable salt thereof. SEQUENCE LISTING [ 0008 ] In another embodiment of the foregoing aspects , [0002 ] The instant application contains a Sequence Listing the vasopressin Vla receptor antagonist is selected from the which has been submitted electronically in ASCII format group consisting of a small interfering RNA (siRNA ), a and is hereby incorporated by reference in its entirety . Said microRNA , an antisense nucleic acid , a ribozyme, an anti ASCII copy , created on Oct . 16 , 2017 , is named 123756 body , and a peptide or peptide analogue . 00202 _ SL . txt and is 18 ,622 bytes in size . [ 0009 ] In another embodiment of the foregoing aspects , wherein the vasopressin Vla receptor antagonist does not BACKGROUND cross the blood brain barrier. In another embodiment of the foregoing aspects , the vasopressin Vla receptor antagonist [ 0003 ] Anorexia nervosa is an eating disorder character does cross the blood brain barrier . In another embodiment of ized by food restriction , odd eating habits or rituals , obses the foregoing aspects , the Vla receptor antagonist is admin sion with having a thin figure , and an irrational fear of istered via injection . In another embodiment of the forego weight gain .
Load more

Recommended publications
  • Neural Basis for Regulation of Vasopressin Secretion by Presystemic Anticipated Disturbances in Osmolality, and by Hypoglycemia
    Neural Basis for Regulation of Vasopressin Secretion by Presystemic Anticipated Disturbances in Osmolality, and by Hypoglycemia The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Kim, Angela. 2020. Neural Basis for Regulation of Vasopressin Secretion by Presystemic Anticipated Disturbances in Osmolality, and by Hypoglycemia. Doctoral dissertation, Harvard University, Graduate School of Arts & Sciences. Citable link https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37365939 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Neural Basis for Regulation of Vasopressin Secretion by Presystemic Anticipated Disturbances in Osmolality, and by Hypoglycemia A dissertation presented by Angela Kim to The Division of Medical Sciences in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the subject of Neuroscience Harvard University Cambridge, Massachusetts April 2020 © 2020 Angela Kim All rights reserved. Dissertation Advisor: Bradford B. Lowell Angela Kim Neural Basis for Regulation of Vasopressin Secretion by Presystemic Anticipated Disturbances in Osmolality, and by Hypoglycemia Abstract Vasopressin (AVP), released by magnocellular AVP neurons of the hypothalamus, is a multifaceted hormone. AVP regulates many physiological processes including blood osmolality, blood glucose, and blood pressure. In this dissertation, I present two independent studies investigating the neural mechanism for role of AVP in fluid and glucose homeostasis. In regards to regulating water excretion and hence blood osmolality, magnocellular AVP neurons are regulated by two temporally distinct signals: 1) slow systemic signals that convey systemic osmolality information, and 2) rapid ‘presystemic’ signals that anticipate future osmotic challenges.
    [Show full text]
  • (1982), 24(4), 329—337 Pineal Response to Lithium1
    Indian J. Psychiat. (1982), 24(4), 329—337 PINEAL RESPONSE TO LITHIUM1 S. PARVATHI DEVI* A. VENKOBA RAO> PINEAL FUNCTION AND BEHAVIOUR—A until Crowther demonstrated from his REVIEW autopsy studies that pineal calcification The pineal gland in ma.i is an active had nothing to do with mental derange­ endocrine gland throughout life (Wurtman ment. et al., 1964 ; Tapp & Huxley, 1972 ; Interest in the pineal gland lay dormant Cardinali, 1974 ; Reiter et al., 1975 ; Reiter, and the gland was relegated to be a ves- 1978). It elaborates several hormones with tigeal organ until the endocrine nature precise rhythmicity. The chronobiological of the gland was suggested following des­ aspects of the mammalian pineal gland have criptions of pineal tumours associated with been clearly brought out by Reiler (198!) precocious puberty (Kitay, 1954). The defining the circadian rhythms in indole idea of a special relation of pineal gland to metabolism within the pineal of mammals. mind was revived in reports of experiments The two major classes of pineal hormones— with pineal extracts in the treatment of pineal indoles (melatonin, serotonin and schizophrenia (Becker, 1920 ; Eldered et the tryptophols) and the polypeptides are al., 196U; Kitay & Altschule, 1954). The known to influence several physiological isolation and characterisation of the pineal systems including the central nervous system hormone melatonin was a turning point (Cardinali, 1974 and Anton Tay, 1974). in pineal research (Lerner et al., 1958). The association of pineal gland with be­ Since then the pineal gland has been a haviour and mental illness can be traced to focus of intense scientific enquiry revealing Alexandrian school of thought (Herophilus it to be an endocrine gland capable of c.
    [Show full text]
  • Therapeutic Potential of Vasopressin-Receptor Antagonists in Heart Failure
    J Pharmacol Sci 124, 1 – 6 (2014) Journal of Pharmacological Sciences © The Japanese Pharmacological Society Current Perspective Therapeutic Potential of Vasopressin-Receptor Antagonists in Heart Failure Yasukatsu Izumi1,*, Katsuyuki Miura2, and Hiroshi Iwao1 1Department of Pharmacology, 2Applied Pharmacology and Therapeutics, Osaka City University Medical School, Osaka 545-8585, Japan Received October 2, 2013; Accepted November 17, 2013 Abstract. Arginine vasopressin (AVP) is a 9-amino acid peptide that is secreted from the posterior pituitary in response to high plasma osmolality and hypotension. AVP has important roles in circulatory and water homoeostasis, which are mediated by oxytocin receptors and by AVP receptor subtypes: V1a (mainly vascular), V1b (pituitary), and V2 (renal). Vaptans are orally and intravenously active nonpeptide vasopressin-receptor antagonists. Recently, subtype-selective nonpeptide vasopressin-receptor agonists have been developed. A selective V1a-receptor antago- nist, relcovaptan, has shown initial positive results in the treatment of Raynaud’s disease, dysmen- orrhea, and tocolysis. A selective V1b-receptor antagonist, nelivaptan, has beneficial effects in the treatment of psychiatric disorders. Selective V2-receptor antagonists including mozavaptan, lixivaptan, satavaptan, and tolvaptan induce highly hypotonic diuresis without substantially affecting the excretion of electrolytes. A nonselective V1a/V2-receptor antagonist, conivaptan, is used in the treatment for euvolaemic or hypervolemic hyponatremia. Recent basic and clinical studies have shown that AVP-receptor antagonists, especially V2-receptor antagonists, may have therapeutic potential for heart failure. This review presents current information about AVP and its antagonists. Keywords: arginine vasopressin, diuretic, heart failure, vasopressin receptor antagonist 1. Introduction receptor blockers, diuretics, b-adrenoceptor blockers, digitalis glycosides, and inotropic agents (4).
    [Show full text]
  • Assessment of Novel Drugs for Treating Preterm Labour Using a Translational Model
    Assessment of novel drugs for treating preterm labour using a translational model A thesis submitted to the University of Manchester for the degree of Doctor of Philosophy in the Faculty of Biology, Medicine and Health 2020 Ammar Ahmed Mohammed School of Health Sciences Division of Pharmacy and Optometry 1 Table of contents Table of contents .............................................................................................. 2 List of Figures .................................................................................................................. 9 List of Tables ................................................................................................................. 20 List of abbreviations ..................................................................................................... 22 Publications .................................................................................................................... 27 Abstract .. ....................................................................................................................... 28 Declaration ..................................................................................................................... 29 Acknowledgements ........................................................................................................ 30 Dedication ...................................................................................................................... 32 1 Chapter 1: ...........................................................................................
    [Show full text]
  • The Oxytocin/Vasopressin Receptor Family Has at Least Five Members in the Gnathostome Lineage, Including Two Distinct V2 Subtypes
    The oxytocin/vasopressin receptor family has at least five members in the gnathostome lineage, including two distinct V2 subtypes General and Comparative Endocrinology 175(1): 135-143 doi:10.1016/j.ygcen.2011.10.011 Accepted October 20, 2011 E-pub October 28, 2012 Published January 1, 2012 Figshare doi:10.6084/m9.figshare.811860. Shared October 1, 2013 Daniel Ocampo Daza*, Michalina Lewicka¹, Dan Larhammar Department of Neuroscience, Science for Life Laboratory, Uppsala Universitet, Box 593, SE-751 24 Uppsala, Sweden * Corresponding author. E-mail address: [email protected] ¹ Current address: Department of Neuroscience, Karolinska Institutet, SE-171 77 Stockholm, Sweden Cite as D. Ocampo Daza, M. Lewicka and D. Larhammar. The oxytocin/vasopressin family has at least five members in the gnathostome lineage, including two distinct V2 subtypes. General and Comparative Endocrinology, 175 (1) (2012) 135-143. This document corresponds to the article as it appeared upon acceptance. You are free to download, print and distribute it for any purposes under a Creative Commons Attribution 3.0 Unported License (http://creativecommons.org/licenses/by/3.0/), provided the original work is cited as specified. Errata: The introduction incorrectly states that “the V2 receptor inhibits adenylyl cyclase, thereby reducing the production of cAMP” on page 3. In fact the V2-type vasopressin receptors stimulate adenylyl cyclase and increase the cytosolic cyclic AMP release, see for instance Schöneberg et al., Molecular aspects of vasopressin receptor function, Advances in experimental medicine and biology 449 (1998) 347–58. This mistake was reported in the proofreading phase of pre-publication, but the correction was not carried to the final version of the article.
    [Show full text]
  • Vasopressin V2 Is a Promiscuous G Protein-Coupled Receptor That Is Biased by Its Peptide Ligands
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.28.427950; this version posted January 28, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Vasopressin V2 is a promiscuous G protein-coupled receptor that is biased by its peptide ligands. Franziska M. Heydenreich1,2,3*, Bianca Plouffe2,4, Aurélien Rizk1, Dalibor Milić1,5, Joris Zhou2, Billy Breton2, Christian Le Gouill2, Asuka Inoue6, Michel Bouvier2,* and Dmitry B. Veprintsev1,7,8,* 1Laboratory of Biomolecular Research, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland and Department of Biology, ETH Zürich, 8093 Zürich, Switzerland 2Department of Biochemistry and Molecular medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada 3Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA 4The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, United Kingdom 5Department of Structural and Computational Biology, Max Perutz Labs, University of Vienna, Campus-Vienna-Biocenter 5, 1030 Vienna, Austria 6Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi 980-8578, Japan. 7Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, UK. 8Division of Physiology, Pharmacology & Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, NG7 2UH, UK. *Correspondence should be addressed to: [email protected], [email protected], [email protected].
    [Show full text]
  • Vaptans: a New Option in the Management of Hyponatremia
    [Downloaded free from http://www.ijabmr.org on Monday, August 18, 2014, IP: 218.241.189.21] || Click here to download free Android application for this journal Educational Forum Vaptans: A new option in the management of hyponatremia Suruchi Aditya, Aditya Rattan1 Department of Pharmacology, Dr. Harvansh Singh Judge Institute of Dental Sciences, Chandigarh. 1Consultant Cardiologist, Heartline, Panchkula, Haryana, India Abstract Arginine vasopressin (AVP) plays an important role in water and sodium homeostasis. It acts via three receptor subtypes— V1a, V 1b, and V2—distributed widely throughout the body. Vaptans are nonpeptide vasopressin receptor antagonists (VRA). By property of aquaresis, VRAs offer a novel therapy of water retention. Conivaptan is a V1a/V2 nonselective VRA approved for euvolemic and hypervolemic hyponatremia. Tolvaptan is the first oral VRA. Other potential uses of this new class of drugs include congestive heart failure (CHF), cirrhosis of liver, syndrome of inappropriate secretion of antidiuretic hormone, polycystic kidney disease, and so on. These novel drugs score over diuretics as they are not associated with electrolyte abnormalities. Though much remains to be elucidated before the VRAs are applied clinically, the future holds much promise. Key words: Aquaresis, hyponatremia, syndrome of inappropriate antidiuretic hormone secretion, vaptan, vasopressin receptor antagonists Introduction hormone (ADH), renin angiotensin aldosterone system (RAAS), sympathetic nervous system (SNS), and thirst help Hyponatremia, one of the most common electrolyte to control water homeostasis in the body and keep plasma abnormalities in hospitalized patients, is defined as serum osmolality between 275 and 290 mOsm/kg water. sodium concentration <135 mEq/L. Its prevalence is one in five of all hospitalized patients.[1] Recent clinical data suggests Hyponatremia can be associated with low, normal, or high that hyponatremia is not only a marker of disease severity but tonicity.
    [Show full text]
  • 1 Advances in Therapeutic Peptides Targeting G Protein-Coupled
    Advances in therapeutic peptides targeting G protein-coupled receptors Anthony P. Davenport1Ϯ Conor C.G. Scully2Ϯ, Chris de Graaf2, Alastair J. H. Brown2 and Janet J. Maguire1 1Experimental Medicine and Immunotherapeutics, Addenbrooke’s Hospital, University of Cambridge, CB2 0QQ, UK 2Sosei Heptares, Granta Park, Cambridge, CB21 6DG, UK. Ϯ Contributed equally Correspondence to Anthony P. Davenport email: [email protected] Abstract Dysregulation of peptide-activated pathways causes a range of diseases, fostering the discovery and clinical development of peptide drugs. Many endogenous peptides activate G protein-coupled receptors (GPCRs) — nearly fifty GPCR peptide drugs have been approved to date, most of them for metabolic disease or oncology, and more than 10 potentially first- in-class peptide therapeutics are in the pipeline. The majority of existing peptide therapeutics are agonists, which reflects the currently dominant strategy of modifying the endogenous peptide sequence of ligands for peptide-binding GPCRs. Increasingly, novel strategies are being employed to develop both agonists and antagonists, and both to introduce chemical novelty and improve drug-like properties. Pharmacodynamic improvements are evolving to bias ligands to activate specific downstream signalling pathways in order to optimise efficacy and reduce side effects. In pharmacokinetics, modifications that increase plasma-half life have been revolutionary. Here, we discuss the current status of peptide drugs targeting GPCRs, with a focus on evolving strategies to improve pharmacokinetic and pharmacodynamic properties. Introduction G protein-coupled receptors (GPCRs) mediate a wide range of signalling processes and are targeted by one third of drugs in clinical use1. Although most GPCR-targeting therapeutics are small molecules2, the endogenous ligands for many GPCRs are peptides (comprising 50 or fewer amino acids), which suggests that this class of molecule could be therapeutically useful.
    [Show full text]
  • Hypernatremia: 2 Months Back When He Had Progressive Decrease in Vision (Right > Left)
    Correspondence to increased intrathoracic pressure and central radiologist regarding vascular injury when there is venous pressure, decreased venous return from the refractory hypotension so that necessary steps can be brain and increased ICP[4] taken to identify and treat iatrogenic complications that • Patients with aneurysmal SAH have disturbed might compound the pre‑existing morbidity. autoregulation of cerebral blood flow. Hence, intraoperative hypotension of any cause has an REFERENCES adverse effect on the outcome of SAH[5,6] • Patients with poor grade SAH (Fischer III/IV) and 1. Young WL, Pile-Spellman J. Anesthetic considerations for interventional Neuroradiolgy (Review). Anesthesiology angiographic evidence of vasospasm which our 1994;80:427-56. patient had, are at risk for cerebral hypoperfusion 2. Varma MK, Price K, Jayakrishnan V, Manickam B, Kessell G. because of impaired cerebral autoregulation and Anaesthetic considerations for interventional neuroradiology. thus intraoperative hypotension and cerebral Br J Anaesth 2007;99:75-85. [6,7] 3. Kent KC, Moscucci M, Mansour KA, Dimattia S, Gallagher S, hypoperfusion compounds the poor outcome Kuntz R, et al. Retroperitoneal hematoma after cardiac • Blood loss leading to severe anaemia (Hb 3.8 g%) catheterization: Prevalence, risk factors, and optimal during the procedure might have lead to decreased management. J Vasc Surg 1994;20:905-10. oxygen‑carrying capacity of blood and further 4. De Laet I, Citerio G, Malbrain ML. The influence of exacerbate the hypoxic injury to brain. intraabdominal hypertension on the central nervous system: Current insights and clinical recommendations, is it all in the Thus a combination of age, poor grade SAH, diffuse head? Acta Clin Belg Suppl 2007;1:89-97.
    [Show full text]
  • New Approaches of the Hyponatremia Treatment in the Elderly – an Update
    FARMACIA, 2020, Vol. 68, 3 https://doi.org/10.31925/farmacia.2020.3.5 REVIEW NEW APPROACHES OF THE HYPONATREMIA TREATMENT IN THE ELDERLY – AN UPDATE ALICE BĂLĂCEANU 1,2#, SECIL OMER 1,2, SILVIU ADRIAN MARINESCU 1,3*, SILVIU MIREL PIȚURU 1#, ȘERBAN DUMITRACHE 2#, DANIELA ELENA POPA 1, ANDREEA ANTONIA GHEORGHE 2, SIRAMONA POPESCU 3, CĂTĂLIN BEJINARIU 3, OCTAV GINGHINĂ 1,2, CARMEN GIUGLEA 1,2 1“Carol Davila” University of Medicine and Pharmacy, 37 Dionisie Lupu Street, 020021, Bucharest, Romania 2“Sf. Ioan” Clinical Emergency Hospital, 13 Vitan-Bârzești Road, 042122, Bucharest, Romania 3“Bagdasar Arseni” Clinical Emergency Hospital, 12 Berceni Road, 041915, Bucharest, Romania *corresponding author: [email protected] #Authors with equal contribution. Manuscript received: December 2019 Abstract Hyponatremia (hNa) is a frequently common imbalance in the elderly hospitalized patients. It is often correlated with elevated plasma quantities of arginine vasopressin (AVP, the antidiuretic hormone) and namely it depicts a water surplus in order to prevail sodium levels. It can conduct, in a comprehensive range, to detrimental changes that can affect the entire health status, especially the central nervous system, thus increasing the mortality and morbidity of hospitalized patients in care units. The inherent treatment of hNa, mainly of the chronic form, requires the correction of serum sodium concentrations at the appropriate rate, because, augmenting it at a warp speed, it can determine permanent or fatal neurologic sequelae. In this regard, the therapy for hNa may be enlightened by egressing therapies that include vasopressin V2 and V1a receptors antagonists, with the principal role of encouraging aquaresis and rise the serum sodium levels, alongside with the electrolyte- sparing discharge of free water.
    [Show full text]
  • Program Book
    ASCP Annual Meeting FAIRMONT SCOTTSDALE PRINCESS MAY 30-JUNE 3, 2016 www.ASCPMeeting.org Dear Colleagues, Welcome to Arizona! On behalf of the American Society of Clinical Psychopharmacology (ASCP) I am pleased to welcome you to our very exciting annual meeting. I want to thank both the Program Committee and the Steering Committee for their wonderful work putting together an extraordinary meeting. Our meeting includes not only a very stimulating Latin American Satellite Symposia but also the 24th iteration of our very successful New Investigators’ Program. Our meeting has something for everyone. There are sessions that discuss innovation across not only syndrome-states and the life cycle but also in terms of public-private partnerships, teaching, as well as public health and dissemination research. And just when you think there could be nothing more to entice you out of the Arizona sun, there are talks on the challenges posed by medical marijuana, to the role of technology in research and clinical practice to a session that describes how you can learn “new tricks” by studying an old medication, Lithium. There is, of course, the very important and unique Regulatory Session that traditionally serves as the closing session of our meeting. The ASCP is committed to finding and testing new therapies for our patients. We want to advance not only the field of psychopharmacology but treatment research in general. Many advances first presented at our annual meeting over the years have become mainstays not only in our treatment of serious mental disorders but in the way we design and conduct our clinical trials.
    [Show full text]
  • "Hyponatremia"[Text Word]) OR "Hyponatremic"[Text Word]
    SYSTEMATIC MAPPING SEARCH STRATEGY PubMed "Hyponatremia"[Mesh] ("hyponatremia"[Text Word]) OR "hyponatremic"[Text Word] ("euvolemic"[Text Word]) OR "hypervolemic"[Text Word] "Inappropriate ADH Syndrome"[Mesh] "antidiuretic hormone"[Text Word] "Heart Failure"[Mesh] "heart failure"[Text Word] "Liver Cirrhosis"[Mesh] ("cirrhosis"[Text Word]) OR "ascites"[Text Word] "Receptors, Vasopressin"[Mesh] "Antidiuretic Hormone Receptor Antagonists"[Mesh] ("v2"[Text Word]) OR "v1a"[Text Word] (("vaptans"[Text Word]) OR "aquaretic"[Text Word]) OR "aquaresis"[Text Word] ("tolvaptan"[Text Word]) OR "opc 41061"[Text Word] ("conivaptan"[Text Word]) OR "ym087"[Text Word] ("satavaptan"[Text Word]) OR "sr121463b"[Text Word] ("lixivaptan"[Text Word]) OR "vpa 985"[Text Word] ("mozavaptan"[Text Word]) OR "opc 31260"[Text Word] "Clinical Trials as Topic"[Majr] "Controlled Clinical Trials as Topic"[Majr] "Randomized Controlled Trials as Topic"[Majr] "Clinical Trial" [Publication Type] "Controlled Clinical Trial" [Publication Type] "Randomized Controlled Trial" [Publication Type] "Random Allocation"[Majr] (("random"[Text Word]) OR "randomly"[Text Word]) OR "randomization"[Text Word] "trial"[Text Word] "Double-Blind Method"[Majr] "Single-Blind Method"[Majr] "double blind"[Text Word] "single blind"[Text Word] "open label"[Text Word] "Placebos"[Majr] "placebo"[Text Word] "post hoc"[Text Word] "subgroup"[Text Word] "extension"[Text Word] OvidMedline(R) Journals@Ovid (Sumarios y Resúmenes todas las Revistas Ovid), Revistas Subscritas a Texto Completo por Sacyl, OvidMEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citantions, Ovid MEDLINE(R) Daily, Ovid MEDLINE and Versions(R) exp Hyponatremia/ hyponatr$.tw. (euvolemic or hypervolemic).tw. exp Inappropriate ADH Syndrome/ (antidiuretic adj hormone).tw. exp Heart Failure/ (heart adj failure).tw. exp Liver Cirrhosis/ (cirrhosis or ascites).tw.
    [Show full text]